MedPharm Secures Commercial Manufacturing & Supply Agreement for First-to-File Generic Topical Product

MedPharm Secures Commercial Manufacturing & Supply Agreement for First-to-File Generic Topical Product

DURHAM, N.C., November 10, 2026 - MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced the addition of a first-to-file generic topical product to its commercial manufacturing portfolio. Under the agreement, MedPharm will serve as the commercial manufacturing and supply partner for the product.

The agreement represents MedPharm's sixth commercial deal secured in the last 22 months, demonstrating the accelerating growth of its commercial manufacturing portfolio and the breadth of expertise resident in the organization. The agreement also builds on the company's nearly three decades of specialization in topical and transepithelial drug products and reflects the increasing demand for MedPharm's expertise in topical pharmaceutical products.

The deal marks an expansion of MedPharm's capabilities into first-to-file generic topical drug products. The product will be manufactured at MedPharm's 110,000 sq. ft. commercial manufacturing facility in Durham, North Carolina, which brings together specialized manufacturing and analytical capabilities, purpose-built infrastructure and an experienced team to support commercial production and supply of topical drug products.

"This agreement is another significant milestone reflecting the business's escalating growth," said Bill Humphries, Chief Executive Officer, MedPharm. "Adding a first-to-file generic topical product to our commercial portfolio reflects the breadth of programs we can support and the value of our specialized expertise in topical drug products. The MedPharm team looks forward to supporting our partner through commercial manufacturing and supply."

About MedPharm

MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With its 2024 merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development and formulation to large batch commercial manufacturing and distribution.

For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 110,000 sq. ft. state-of-the-art manufacturing facility in Durham, North Carolina. For more information, visit medpharm.com or follow us on LinkedIn.

Media Contacts:

Sadie Smith, Marketing and Events Coordinator

E: [email protected]

Miles Fisher-Pollard, Orientation Marketing

E: [email protected]